【摘要】 目的研究3种常用非甾体抗炎药(NSAID)治疗类风湿关节炎(RA)的经济效果和安全性。方法选择病情处于活动期的RA患者180例,随机分为A、B、C 3组,每组60例。A组选用布洛芬缓释胶囊;B组选用双氯芬酸缓释胶囊;C组选用美洛昔康片。基础用药与检查各组均相同。运用药物经济学的成本-效果分析方法对各组进行评价。结果3组方案治疗RA的成本平均每例分别为:A组(209.71±80.13)元,B组(291.36±100.89)元,C组(262.44±47.58)元;有效率依次为:66.7%、81.7%、76.7%;每获得一个单位效果,依次需花费成本3.14元、3.57元、3.42元;不良反应的发生率依次为:20.0%、33.3%、15.0%。在A方案的基础上,每获1个单位效果,方案B、C所花费的成本分别为:5.44元、5.27元。结论A方案成本最低,但有效率较低;B方案有效率最高,但不良反应发生率亦最常见。RA患者选用C方案为宜。更多还原

【Abstract】 Objective To investigate the economic effect and safety of three nonsteroidal anti-inflammatory drugs(NSAIDs) in treatment of rheumatoid arthritis(RA).Methods One hundred and eighty patients with RA at active stage were randomly divided into three groups: group A,B and C,each group was 60 cases.The patients of group A,B and C were given Ibuprofen Sustained Release Capsules,Diclofenac Sustained-release Capsules and meloxicam tablets respectively.The obtained data were evaluated by the pharmacoeconomic cost-effectiveness analysis.Results The average costs of each patient in group A,B and C were 209.71±80.13,291.36±100.89 and 262.44±47.58 yuans respectively.The effective rates of three groups were 66.7%,81.7% and 76.7%,respectively.The costs of three therapeutic regimen of A,B and C were 3.14,3.57 and 3.42 yuans,respectively for increasing 1% of effective rate.The incidence rate of adverse reaction in groups of A,B and C were 20.0%,33.3% and 15.0%,respectively.On the foundation of A therapeutic regimen,the average costs of each patient in groups of B and C were 5.44 and 5.27 yuans respectively,for increasing 1% of effective rate.Conclusions Among three therapeutic regimens,the cost of regimen A was the lowest,but the effective rate was also the lowest.The effective rate of the regimen B was the highest,but the incidence rate of adverse reaction in groups of B was the highest too.So that,regimen C was a best regimen for common patients of RA.更多还原